Skip to main content

Table 1 Univariate and Multivariate Analysis of YAP1/FAPα and Clinical Characteristics for Metastasis-Free Survival of NPC Patients

From: Epstein-Barr viral product-containing exosomes promote fibrosis and nasopharyngeal carcinoma progression through activation of YAP1/FAPα signaling in fibroblasts

YAP1

Univariate analysis

 

Multivariate analysis

 

n = 106

HR (95% CI)

p value

HR (95% CI)

p value

YAP1 Score (≥80 vs. < 80)

2.470 (1.057–5.776)

0.037

4.834 (1.857–12.579)

0.001

Treatment Daysa

1.105 (1.008–1.21)

0.032

1.190 (1.069–1.325)

0.001

BEDa

1.05 (0.875–1.155)

0.945

0.896 (0.772–1.040)

0.148

Age Group (≥48 vs. < 48)

0.830 (0.372–1.853)

0.65

0.727 (0.258–2.046)

0.546

Gender (Male vs. Female)

2.806 (0.837–9.410)

0.095

4.020 (1.007–16.059)

0.049

T-Stage (T3/4 vs. T1/2)

1.519 (0.675–3.419)

0.313

2.085 (0.750–5.800)

0.159

N-Stage (N2/3 vs. N0/1)

1.717 (0.762–3.867)

0.192

1.989 (0.817–4.843)

0.13

Chemotherapy (Yes vs. No)

0.891 (0.332–2.385)

0.818

0.616 (0.207–1.832)

0.384

Comorbidity (Yes vs. No)

1.161 (0.516–2.615)

0.718

1.416 (0.543–3.693)

0.477

Smoking (Yes vs. No)

1.516 (0.663–3.465)

0.324

1.098 (0.413–2.916)

0.851

Betel quid (Yes vs. No)

1.619 (0.671–3.905)

0.283

1.353 (0.382–4.798)

0.64

Alcohol (Yes vs. No)

1.263 (0.561–2.845)

0.572

0.913 (0.300–2.780)

0.873

FAPα

Univariate analysis

 

Multivariate analysis

 

n = 143

HR (95% CI)

p value

HR (95% CI)

p value

FAPα Score (≥80 vs. < 80)

2.221 (0.995–4.959)

0.051

2.867 (1.127–7.291)

0.027

Treatment Daysa

1.070 (0.994–1.152)

0.072

1.078 (0.984–1.180)

0.105

BEDa

1.036 (0.952–1.127)

0.417

0.991 (0.911–1.078)

0.835

Age Group (≥48 vs. < 48)

0.742 (0.332–1.656)

0.466

0.526 (0.196–1.409)

0.201

Gender (Male vs. Female)

4.424 (1.040–18.813)

0.044

6.189 (1.334–28.724)

0.02

T-Stage (T3/4 vs. T1/2)

2.037 (0.871–4.762)

0.01

2.031 (0.748–5.512)

0.164

N-Stage (N2/3 vs. N0/1)

2.782 (1.153–6.710)

0.023

2.756 (1.111–6.833)

0.029

Chemotherapy (Yes vs. No)

0.730 (0.290–1.840)

0.505

0.594 (0.211–1.670)

0.323

Comorbidity (Yes vs. No)

1.392 (0.577–3.357)

0.462

1.047 (0.396–2.769)

0.926

Smoking (Yes vs. No)

1.114 (0.495–2.508)

0.794

0.482 (0.184–1.264)

0.138

Betel quid (Yes vs. No)

1.454 (0.603–3.508)

0.404

1.231 (0.403–3.762)

0.715

Alcohol (Yes vs. No)

1.181 (0.505–2.759)

0.701

0.928 (0.289–2.983)

0.9

  1. acontinuous variable; BED, Biologically effective dose, HR Hazard ratio, CI Confidence interval